Welcome to our dedicated page for Swk Hldgs SEC filings (Ticker: SWKH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for the numbers behind SWK Holdings’ royalty-backed loans or Enteris BioPharma milestones? Investors typically open a filing to track how much cash those life-science royalties generate, whether credit-quality on finance receivables is shifting, and when executives buy or sell shares. That information lives deep inside the SWK Holdings annual report 10-K, every SWK Holdings quarterly earnings report 10-Q filing, and a steady stream of 8-Ks.
Stock Titan’s AI platform turns that search into a two-minute task. Type a natural question—“understanding SWK Holdings SEC documents with AI” or “SWK Holdings insider trading Form 4 transactions”—and receive an instant summary that pinpoints royalty income tables, allowance for credit losses, and segment results. Real-time alerts flag SWK Holdings Form 4 insider transactions as soon as they reach EDGAR, while our side-by-side redlines highlight material changes between periods.
You’ll also find:
- 8-K material events explained in plain English, so you can gauge new loan originations or Enteris partnership updates without dissecting legal language.
- Proxy statement executive compensation breakdowns that link pay to portfolio performance.
- Concise tables comparing revenue‐share percentages across each financed asset—critical for anyone performing a SWK Holdings earnings report filing analysis.
Whether you need a quick view of SWK Holdings executive stock transactions Form 4 or a deeper dive into credit‐risk footnotes, our comprehensive archive and AI-powered summaries keep every SEC filing explained simply—no spreadsheet sprawl, no jargon chase.
SWK Holdings outlined terms of its proposed merger with Runway Growth Finance (RWAY), combining cash and stock consideration determined shortly before closing. The cash portion from RWAY will be calculated from SWK’s NAV determined 48 hours prior to close, less deferred tax assets, intangible assets, and SWK transaction expenses, then reduced by a fixed $75.5M book-value stock component. An additional $9.0M cash payment will come from RWAY’s external manager.
SWK shareholders will receive a fixed $75.5M of RWAY shares, subject to a 19.9% cap relative to RWAY’s outstanding common stock. Using RWAY’s NAV per share of $13.55 as of 9/30/25, this equates to roughly 5.572M shares; based on a 20‑day VWAP of $9.85 as of November 6, 2025, the stock component’s market value was about $54.9M. The company targets an expected close in early 2026, notes a change‑of‑control bond offer to call at par, and indicates the transaction is expected to be a taxable event.
Runway Growth Finance discussed Q3 2025 results and its proposed merger to acquire SWK Holdings, a healthcare and life sciences lender. Runway reported total investment income of $36.7 million and net investment income of $15.7 million, completing $128.3 million of funded loans across technology, healthcare and select consumer sectors.
The portfolio had $946 million in fair value, a debt yield of 16.8%, and one non‑accrual loan with a fair value of $2.4 million (0.2% of the portfolio). NAV per share was $13.55; leverage was 0.92x. Liquidity totaled $371.9 million with borrowing capacity of $364.0 million. The board declared a Q4 regular distribution of $0.33 per share; Q3 NII was $0.43 per share with spillover income of $0.53.
The parties announced a NAV‑for‑NAV merger with an estimated purchase price of ~$220 million, including $75.5 million in Runway shares valued at closing NAV and ~$145 million in cash, plus a $9 million cash contribution from the adviser. Runway expects mid‑single digit run‑rate NII accretion in the first full quarter post‑close and to increase healthcare exposure to about 31% from 14%. Closing is anticipated in early 2026.
Runway Growth Finance Corp. announced a proposed merger with SWK Holdings Corporation and outlined expected financial and portfolio impacts. The company anticipates mid single-digit run-rate net investment income (NII) accretion during the first full quarter following closing, with pro forma leverage moving to ~1.1x. Management highlighted potential benefits including enhanced scale, broader funding access, and a lowered risk profile from smaller average loan positions.
Operationally, the portfolio at fair value was $946 million as of September 30, 2025, with a weighted average debt investment yield of 16.83%. For the same period, NAV per share was $13.55 and NII per share was $0.43. The platform reported 98% first lien exposure and a cumulative net loss rate of 0.61% since inception, supported by disciplined underwriting and active monitoring. Management also cited improved trading liquidity and funding flexibility as potential post-combination advantages, subject to completion of the merger and customary conditions.
SWK Holdings reported solid Q3 results as it completes its shift to a single operating segment. For the quarter ended September 30, 2025, revenue was
The finance book generated interest income of
Strategically, the company sold most of its royalty portfolio to Soleus for approximately
SWK Holdings Corporation announced the full repayment of its loan to Elutia, receiving a $27.8 million payoff that exceeds the company’s net GAAP carrying value of $23.9 million as of June 30, 2025. The repayment follows Elutia’s sale of its BioEnvelope business to Boston Scientific for $88.0 million in cash. SWK expects to recognize approximately $1.4 million of incremental income from acceleration of exit fee recognition and approximately $1.4 million from the release of loan loss reserves, reflecting a net benefit to the company’s reported results from this transaction.
SWK Holdings Corporation (SWKH) reported interim financials focused on two segments: specialty finance (Finance Receivables) and Pharmaceutical Development (MOD3). As of June 30, 2025, the company held $237.6 million of net finance receivables and $8.0 million in cash, up from $5.9 million at year-end 2024. During the period the company sold a royalty portfolio for approximately $34.0 million, recording a $3.7 million lower-of-cost-or-market loss. The Board declared a $4.00 per share special cash dividend payable May 8, 2025. The company maintains a revolving credit facility (initially $45.0 million, commitments increased to $60.0 million) and $30.0 million of 9.00% senior notes due 2027. Assets and liabilities of the MOD3 CDMO business are classified as held for sale pending Aptar’s option exercise, aligning the company toward the specialty finance strategy. Unfunded commitments totaled $7.5 million.
FAQ
What is the current stock price of Swk Hldgs (SWKH)?
What is the market cap of Swk Hldgs (SWKH)?
